Cinclus Pharma Holding AB’s drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) ahead of its planned commercial launch.

• Status: Inclusion in the NRDL will enable broader patient access to the treatment for gastroesophageal reflux disease (GERD) across mainland China.
• Application: Linaprazan glurate is developed for the treatment of GERD, addressing an unmet medical need for patients with severe acid‑related disease.
• Timeline: The product is expected to be launched on the Chinese market in 2026 by Cinclus Pharma’s licensee and co‑developer in China and its commercial partner.

This summary is based on a press release issued by Cinclus Pharma.